American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(suppl 1):S181-S206.
3.
PhillipsLSBranchWTCookCB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.
4.
LimonteCPHallYNTrikudanathanS, et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complications. 2022;36(6):108204. doi:10.1016/j.jdiacomp.2022.108204
5.
ReachGPechtnerVGentilellaRCorcosACerielloA.Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501-511.
6.
GabbayRAKendallDBeebeC, et al. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin Diabetes. 2020;38(4):371-381.
7.
Lamprea-MontealegreJAMaddenETummalapalliSL, et al. Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration System. JAMA. 2022;328(9):861-871.
8.
PowellREZaccardiFBeebeC, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(9):2137-2154.
Boston University Chobanian and Avedisian School of Medicine, Barry M. Manuel Center for Continuing Education. Using your GLP-1 or GLP-1/GIP pens: a patient education resource. 2025. Accessed September 20, 2025. https://cme.bu.edu/glp1penteaching
11.
GreenwoodDAHowellFScherL, et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: the role of the diabetes care and education specialist. Diabetes Educ. 2020;46(4):315-322.
